Apoquel 5.4mg Tablets

Apoquel 5.4 mg Tablets contain oclacitinib, a veterinary medicine used to control itching associated with allergic dermatitis and treat the clinical signs of atopic dermatitis in dogs.

Oclacitinib works by inhibiting specific enzymes involved in inflammatory and allergic signalling, helping reduce itching and associated skin symptoms.

Apoquel is a prescription veterinary medicine. Treatment should be selected and monitored by a veterinarian to assess suitability, response and potential adverse effects.

Product Information

Product Name

Apoquel 5.4 mg Tablets

Active Ingredient

Oclacitinib (as oclacitinib maleate)

Strength

5.4 mg per tablet

Dosage Form

Oral film-coated tablet

Brand

Apoquel

Manufacturer/Marketing Authorization Holder

Verify current packaging

Target Species

Dogs

Therapeutic Category

Veterinary dermatology

Indications

Pruritus associated with allergic dermatitis and clinical manifestations of atopic dermatitis

Route of Administration

Oral

Pack Size

Confirm available packaging

Prescription Status

Subject to local veterinary medicine regulations

Ordering and Availability

For Apoquel 5.4 mg tablet prices, pack sizes and availability, contact the supplier to confirm the exact product presentation, manufacturer, current stock and prescription requirements.

Product authorization, veterinary dispensing rules and import eligibility vary by country. Confirm local requirements and obtain Apoquel through an authorized veterinary pharmacy or eligible supplier.

Apoquel 5.4 mg Tablets may be prescribed by a veterinarian for:

• Allergic Dermatitis: Helps control itching associated with allergic skin conditions in dogs.
• Atopic Dermatitis: Helps manage the clinical signs of canine atopic dermatitis.
• Itch Management: May reduce scratching and associated discomfort when used as directed.

Apoquel helps control symptoms but does not eliminate every underlying cause of skin disease. Fleas, food allergies, infections and other dermatological problems may require additional investigation or treatment.

Give Apoquel 5.4 mg Tablets only according to the veterinarian's instructions. The appropriate dose and treatment schedule depend on the dog's body weight, clinical condition and response to treatment.

Follow the veterinary prescription and the product leaflet for administration instructions. Do not increase the dose, change the frequency or extend treatment without consulting the veterinarian.

Apoquel film-coated tablets are designed for oral administration. Confirm the exact product presentation before use, as chewable formulations may have separate packaging instructions.

Storage Instructions

Store Apoquel according to the manufacturer's label and package leaflet. The referenced film-coated tablet product information specifies storage below 25°C and keeping the blister in the outer carton.

Follow the package instructions for unused tablet halves and discard them within the period stated in the leaflet. Keep the medicine out of the reach of children and animals, and do not use it after the expiry date.

Possible adverse effects include:

• Vomiting or diarrhoea
• Reduced appetite
• Lethargy
• Increased susceptibility to infections
• Skin or ear infections

Oclacitinib affects immune signalling and may increase susceptibility to infection or worsen certain neoplastic conditions. Monitor the dog for unusual symptoms and arrange veterinary assessment when necessary.

Contact a veterinarian promptly if the dog develops persistent vomiting, significant lethargy, worsening skin lesions, signs of infection or other unexpected symptoms.

Before treatment, tell the veterinarian about the dog's medical history, current medicines, vaccination status and any existing infections or tumours.

Important precautions include:

• Age and body weight: The referenced UK/EU product information contraindicates use in dogs younger than 12 months or weighing less than 3 kg.
• Immune suppression: The medicine should not be used in dogs with evidence of immune suppression, as specified in the product information.
• Neoplasia: Dogs with progressive malignant neoplasia should not receive the medicine under the referenced product labeling.
• Infection monitoring: Monitor for infections and other adverse effects during treatment.
• Veterinary supervision: Do not use this medicine without appropriate veterinary advice.

The contraindications and approved instructions for the exact product and country must be checked before prescribing.